CA3153531A1 - Cdk inhibitors and their use as pharmaceuticals - Google Patents
Cdk inhibitors and their use as pharmaceuticals Download PDFInfo
- Publication number
- CA3153531A1 CA3153531A1 CA3153531A CA3153531A CA3153531A1 CA 3153531 A1 CA3153531 A1 CA 3153531A1 CA 3153531 A CA3153531 A CA 3153531A CA 3153531 A CA3153531 A CA 3153531A CA 3153531 A1 CA3153531 A1 CA 3153531A1
- Authority
- CA
- Canada
- Prior art keywords
- alkyl
- compound
- fluoro
- membered
- pharmaceutically acceptable
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Pending
Links
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
- A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
- A61K31/4427—Non condensed pyridines; Hydrogenated derivatives thereof containing further heterocyclic ring systems
- A61K31/4439—Non condensed pyridines; Hydrogenated derivatives thereof containing further heterocyclic ring systems containing a five-membered ring with nitrogen as a ring hetero atom, e.g. omeprazole
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
- A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
- A61K31/445—Non condensed piperidines, e.g. piperocaine
- A61K31/4523—Non condensed piperidines, e.g. piperocaine containing further heterocyclic ring systems
- A61K31/4545—Non condensed piperidines, e.g. piperocaine containing further heterocyclic ring systems containing a six-membered ring with nitrogen as a ring hetero atom, e.g. pipamperone, anabasine
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
- A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
- A61K31/506—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim not condensed and containing further heterocyclic rings
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/535—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with at least one nitrogen and one oxygen as the ring hetero atoms, e.g. 1,2-oxazines
- A61K31/5375—1,4-Oxazines, e.g. morpholine
- A61K31/5377—1,4-Oxazines, e.g. morpholine not condensed and containing further heterocyclic rings, e.g. timolol
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
- C07D401/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings
- C07D401/04—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings directly linked by a ring-member-to-ring-member bond
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
- C07D401/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings
- C07D401/08—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings linked by a carbon chain containing alicyclic rings
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
- C07D401/14—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing three or more hetero rings
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D405/00—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom
- C07D405/14—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing three or more hetero rings
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D413/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms
- C07D413/14—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing three or more hetero rings
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D417/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00
- C07D417/02—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00 containing two hetero rings
- C07D417/04—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00 containing two hetero rings directly linked by a ring-member-to-ring-member bond
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D417/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00
- C07D417/02—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00 containing two hetero rings
- C07D417/08—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00 containing two hetero rings linked by a carbon chain containing alicyclic rings
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D417/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00
- C07D417/14—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00 containing three or more hetero rings
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D471/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00
- C07D471/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00 in which the condensed system contains two hetero rings
- C07D471/04—Ortho-condensed systems
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D487/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00
- C07D487/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00 in which the condensed system contains two hetero rings
- C07D487/04—Ortho-condensed systems
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D498/00—Heterocyclic compounds containing in the condensed system at least one hetero ring having nitrogen and oxygen atoms as the only ring hetero atoms
- C07D498/02—Heterocyclic compounds containing in the condensed system at least one hetero ring having nitrogen and oxygen atoms as the only ring hetero atoms in which the condensed system contains two hetero rings
- C07D498/04—Ortho-condensed systems
Landscapes
- Chemical & Material Sciences (AREA)
- Organic Chemistry (AREA)
- Health & Medical Sciences (AREA)
- Veterinary Medicine (AREA)
- General Health & Medical Sciences (AREA)
- Medicinal Chemistry (AREA)
- Public Health (AREA)
- Pharmacology & Pharmacy (AREA)
- Life Sciences & Earth Sciences (AREA)
- Animal Behavior & Ethology (AREA)
- Epidemiology (AREA)
- General Chemical & Material Sciences (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Nitrogen Condensed Heterocyclic Rings (AREA)
- Plural Heterocyclic Compounds (AREA)
- Nitrogen And Oxygen Or Sulfur-Condensed Heterocyclic Ring Systems (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
Applications Claiming Priority (5)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US201962898839P | 2019-09-11 | 2019-09-11 | |
| US62/898,839 | 2019-09-11 | ||
| US202063005577P | 2020-04-06 | 2020-04-06 | |
| US63/005,577 | 2020-04-06 | ||
| PCT/US2020/050326 WO2021050824A1 (en) | 2019-09-11 | 2020-09-11 | Cdk inhibitors and their use as pharmaceuticals |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| CA3153531A1 true CA3153531A1 (en) | 2021-03-18 |
Family
ID=74850746
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| CA3153531A Pending CA3153531A1 (en) | 2019-09-11 | 2020-09-11 | Cdk inhibitors and their use as pharmaceuticals |
Country Status (11)
| Country | Link |
|---|---|
| US (3) | US20220324830A1 (cg-RX-API-DMAC7.html) |
| EP (1) | EP4028005A4 (cg-RX-API-DMAC7.html) |
| JP (1) | JP7763489B2 (cg-RX-API-DMAC7.html) |
| KR (1) | KR20220079851A (cg-RX-API-DMAC7.html) |
| CN (1) | CN114786673A (cg-RX-API-DMAC7.html) |
| AU (1) | AU2020345950A1 (cg-RX-API-DMAC7.html) |
| BR (1) | BR112022004327A2 (cg-RX-API-DMAC7.html) |
| CA (1) | CA3153531A1 (cg-RX-API-DMAC7.html) |
| IL (1) | IL291191A (cg-RX-API-DMAC7.html) |
| MX (1) | MX2022002946A (cg-RX-API-DMAC7.html) |
| WO (1) | WO2021050824A1 (cg-RX-API-DMAC7.html) |
Families Citing this family (11)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| AU2020345950A1 (en) | 2019-09-11 | 2022-03-31 | Prelude Therapeutics Incorporated | CDK inhibitors and their use as pharmaceuticals |
| AU2020401999B2 (en) * | 2019-12-09 | 2024-01-18 | Cspc Zhongqi Pharmaceutical Technology (Shijiazhuang) Co., Ltd. | Compound as cyclin-dependent kinase 9 inhibitor and use thereof |
| CN114605390B (zh) * | 2020-12-04 | 2024-08-16 | 上海凌达生物医药有限公司 | 具有cdk激酶抑制活性的化合物、其药物组合物和用途 |
| CN115381824B (zh) * | 2021-05-24 | 2024-11-05 | 石药集团中奇制药技术(石家庄)有限公司 | 周期蛋白依赖性激酶9抑制剂的用途 |
| WO2022247785A1 (zh) * | 2021-05-24 | 2022-12-01 | 石药集团中奇制药技术(石家庄)有限公司 | 一种周期蛋白依赖性激酶9抑制剂的用途 |
| US20230144528A1 (en) * | 2021-09-30 | 2023-05-11 | Prelude Therapeutics Incorporated | CDK Inhibitors And Their Use As Pharmaceuticals |
| AU2022362075A1 (en) * | 2021-10-14 | 2024-05-09 | Prelude Therapeutics Incorporated | Crystalline forms of a substituted benzimidazole acting as as cdk9 inhibitor and uses thereof |
| WO2025076115A1 (en) * | 2023-10-02 | 2025-04-10 | Prelude Therapeutics Incorporated | Cdk inhibitors and their use as pharmaceuticals |
| WO2025189114A1 (en) | 2024-03-08 | 2025-09-12 | Prelude Therapeutics Incorporated | Cdk inhibitors and their use as pharmaceuticals |
| WO2026024933A1 (en) * | 2024-07-24 | 2026-01-29 | Prelude Therapeutics Incorporated | Cdk inhibitors and their use as pharmaceuticals |
| CN119638640A (zh) * | 2024-12-10 | 2025-03-18 | 杭州亦宁医药技术有限公司 | 一种5-溴-2-甲基-3-异丙基-吲唑的制备方法 |
Family Cites Families (21)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| WO2008070354A2 (en) * | 2006-10-31 | 2008-06-12 | Smithkline Beecham Corporation | 5- and 6- substituted benzimidazole thiophene compounds |
| CA2719059C (en) | 2008-03-27 | 2016-05-17 | Nestec S.A. | Methods for increasing absorption of peptides, peptidomimetics, and other gastrointestinal transport protein substrates |
| US8435980B2 (en) * | 2009-07-15 | 2013-05-07 | Abbvie Inc. | Pyrrolopyridine inhibitors of kinases |
| US9440952B2 (en) * | 2013-03-04 | 2016-09-13 | Merck Sharp & Dohme Corp. | Compounds inhibiting leucine-rich repeat kinase enzyme activity |
| TW201444820A (zh) | 2013-03-13 | 2014-12-01 | Abbvie Inc | 吡啶cdk9激酶抑制劑 |
| WO2015108881A1 (en) * | 2014-01-14 | 2015-07-23 | Millennium Pharmaceuticals, Inc. | Heteroaryls and uses thereof |
| TN2016000270A1 (en) * | 2014-01-14 | 2017-10-06 | Millennium Pharm Inc | Heteroaryls and uses thereof. |
| US10035777B2 (en) | 2014-08-05 | 2018-07-31 | Bristol-Myers Squibb Company | Heterocyclic kinase inhibitors |
| WO2016197078A1 (en) * | 2015-06-05 | 2016-12-08 | Syros Pharmaceuticals, Inc. | Compounds for the modulation of myc activity |
| TR201909286T4 (tr) * | 2015-06-29 | 2019-07-22 | Astrazeneca Ab | CDK9 inhibitörleri olarak polisiklik amid türevleri. |
| US10815432B2 (en) | 2015-09-22 | 2020-10-27 | Hindustan Petroleum Corporation Limited | Additive and a catalyst composition comprising the additive for FCC process |
| FR3041639B1 (fr) | 2015-09-30 | 2019-01-25 | Les Laboratoires Servier | NOUVEAUX DERIVES D'IMIDAZO[4,5-b]PYRIDINE, PROCEDE POUR LES PREPARER ET COMPOSITIONS PHARMACEUTIQUES LES CONTENANT |
| CN107641118B (zh) * | 2016-07-22 | 2020-11-06 | 爱科诺生物医药股份有限公司 | 具有细胞坏死抑制活性的化合物及其组合物和应用 |
| AU2020345950A1 (en) * | 2019-09-11 | 2022-03-31 | Prelude Therapeutics Incorporated | CDK inhibitors and their use as pharmaceuticals |
| AU2020401999B2 (en) * | 2019-12-09 | 2024-01-18 | Cspc Zhongqi Pharmaceutical Technology (Shijiazhuang) Co., Ltd. | Compound as cyclin-dependent kinase 9 inhibitor and use thereof |
| US20230265083A1 (en) * | 2020-08-10 | 2023-08-24 | Prelude Therapeutics Incorporated | Heterocycle CDK Inhibitors And Their Use Thereof |
| EP4214213A1 (en) * | 2020-09-21 | 2023-07-26 | Prelude Therapeutics, Incorporated | Cdk inhibitors and their use as pharmaceuticals |
| IL316942A (en) * | 2020-12-18 | 2025-01-01 | Prelude Therapeutics Inc | CDK inhibitors and their use as drugs |
| US20230144528A1 (en) * | 2021-09-30 | 2023-05-11 | Prelude Therapeutics Incorporated | CDK Inhibitors And Their Use As Pharmaceuticals |
| AU2022362075A1 (en) * | 2021-10-14 | 2024-05-09 | Prelude Therapeutics Incorporated | Crystalline forms of a substituted benzimidazole acting as as cdk9 inhibitor and uses thereof |
| WO2025076115A1 (en) * | 2023-10-02 | 2025-04-10 | Prelude Therapeutics Incorporated | Cdk inhibitors and their use as pharmaceuticals |
-
2020
- 2020-09-11 AU AU2020345950A patent/AU2020345950A1/en not_active Abandoned
- 2020-09-11 BR BR112022004327A patent/BR112022004327A2/pt not_active Application Discontinuation
- 2020-09-11 US US17/642,482 patent/US20220324830A1/en not_active Abandoned
- 2020-09-11 CN CN202080078041.6A patent/CN114786673A/zh active Pending
- 2020-09-11 CA CA3153531A patent/CA3153531A1/en active Pending
- 2020-09-11 MX MX2022002946A patent/MX2022002946A/es unknown
- 2020-09-11 JP JP2022515905A patent/JP7763489B2/ja active Active
- 2020-09-11 EP EP20864098.7A patent/EP4028005A4/en not_active Withdrawn
- 2020-09-11 KR KR1020227011706A patent/KR20220079851A/ko not_active Ceased
- 2020-09-11 WO PCT/US2020/050326 patent/WO2021050824A1/en not_active Ceased
- 2020-09-11 US US17/018,005 patent/US11673893B2/en active Active
-
2022
- 2022-03-08 IL IL291191A patent/IL291191A/en unknown
-
2023
- 2023-04-04 US US18/295,394 patent/US12486277B2/en active Active
Also Published As
| Publication number | Publication date |
|---|---|
| US20210070761A1 (en) | 2021-03-11 |
| IL291191A (en) | 2022-05-01 |
| KR20220079851A (ko) | 2022-06-14 |
| JP2022548568A (ja) | 2022-11-21 |
| CN114786673A (zh) | 2022-07-22 |
| MX2022002946A (es) | 2022-06-14 |
| JP7763489B2 (ja) | 2025-11-04 |
| EP4028005A1 (en) | 2022-07-20 |
| AU2020345950A1 (en) | 2022-03-31 |
| US12486277B2 (en) | 2025-12-02 |
| US11673893B2 (en) | 2023-06-13 |
| US20220324830A1 (en) | 2022-10-13 |
| BR112022004327A2 (pt) | 2022-05-31 |
| US20230242543A1 (en) | 2023-08-03 |
| EP4028005A4 (en) | 2023-09-20 |
| WO2021050824A1 (en) | 2021-03-18 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| US12486277B2 (en) | CDK inhibitors and their use as pharmaceuticals | |
| AU2018313910A1 (en) | Selective inhibitors of protein arginine methyltransferase 5 (PRMT5) | |
| US12129262B2 (en) | CDK inhibitors and their use as pharmaceuticals | |
| WO2023192416A1 (en) | Mutant pi3k-alpha inhibitors and their use as pharmaceuticals | |
| WO2022035799A1 (en) | Heterocycle cdk inhibitors and their use thereof | |
| WO2024211346A1 (en) | Mutant pi3k-alpha inhibitors and their use as pharmaceuticals | |
| US11622970B2 (en) | BCL-2 inhibitors and their use as pharmaceuticals | |
| WO2023056441A1 (en) | Cdk inhibitors and their use as pharmaceuticals | |
| WO2020123994A1 (en) | 2-((5-(phenyl)-pyrrolo[2,1-f][1,2,4]triazin-4-yl)amino)-3-(phenyl)propanoic acid derivatives and related compounds as mcl-1 enzyme inhibitors for treating cancer | |
| US20240246993A1 (en) | CDK Inhibitors And Their Use As Pharmaceuticals | |
| WO2024086789A2 (en) | Mutant pi3k-alpha inhibitors and their use as pharmaceuticals | |
| US20230257394A1 (en) | CDK Inhibitors And Their Use As Pharmaceuticals | |
| WO2025038815A1 (en) | Mutant pi3k-alpha inhibitors and their use as pharmaceuticals | |
| EA049578B1 (ru) | Ингибиторы cdk (циклин-зависимой киназы) и их применение в фармацевтических препаратах | |
| WO2024216249A1 (en) | Cdk inhibitors and their use as pharmaceuticals | |
| HK40031042B (en) | Selective inhibitors of protein arginine methyltransferase 5 (prmt5) | |
| HK40031042A (en) | Selective inhibitors of protein arginine methyltransferase 5 (prmt5) |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| D11 | Substantive examination requested |
Free format text: ST27 STATUS EVENT CODE: A-1-1-D10-D11-D117 (AS PROVIDED BY THE NATIONAL OFFICE); EVENT TEXT: REQUEST FOR EXAMINATION RECEIVED Effective date: 20240712 |
|
| P11 | Amendment of application requested |
Free format text: ST27 STATUS EVENT CODE: A-1-1-P10-P11-P101 (AS PROVIDED BY THE NATIONAL OFFICE); EVENT TEXT: AMENDMENT RECEIVED - VOLUNTARY AMENDMENT Effective date: 20240712 |
|
| P22 | Classification modified |
Free format text: ST27 STATUS EVENT CODE: A-1-1-P10-P22-P110 (AS PROVIDED BY THE NATIONAL OFFICE); EVENT TEXT: CLASSIFICATION MODIFIED Effective date: 20240814 |
|
| D00 | Search and/or examination requested or commenced |
Free format text: ST27 STATUS EVENT CODE: A-1-1-D10-D00-D118 (AS PROVIDED BY THE NATIONAL OFFICE); EVENT TEXT: REQUEST FOR EXAMINATION REQUIREMENTS DETERMINED COMPLIANT Effective date: 20241212 |
|
| P11 | Amendment of application requested |
Free format text: ST27 STATUS EVENT CODE: A-1-1-P10-P11-P102 (AS PROVIDED BY THE NATIONAL OFFICE); EVENT TEXT: AMENDMENT DETERMINED COMPLIANT Effective date: 20241212 |
|
| P13 | Application amended |
Free format text: ST27 STATUS EVENT CODE: A-1-1-P10-P13-X000 (AS PROVIDED BY THE NATIONAL OFFICE); EVENT TEXT: APPLICATION AMENDED Effective date: 20241212 |
|
| W00 | Other event occurred |
Free format text: ST27 STATUS EVENT CODE: A-1-1-W10-W00-W111 (AS PROVIDED BY THE NATIONAL OFFICE); EVENT TEXT: CORRESPONDENT DETERMINED COMPLIANT Effective date: 20241212 |
|
| MFA | Maintenance fee for application paid |
Free format text: FEE DESCRIPTION TEXT: MF (APPLICATION, 4TH ANNIV.) - STANDARD Year of fee payment: 4 |
|
| U00 | Fee paid |
Free format text: ST27 STATUS EVENT CODE: A-1-1-U10-U00-U101 (AS PROVIDED BY THE NATIONAL OFFICE); EVENT TEXT: MAINTENANCE REQUEST RECEIVED Effective date: 20250131 |
|
| U11 | Full renewal or maintenance fee paid |
Free format text: ST27 STATUS EVENT CODE: A-1-1-U10-U11-U102 (AS PROVIDED BY THE NATIONAL OFFICE); EVENT TEXT: MAINTENANCE FEE PAYMENT DETERMINED COMPLIANT Effective date: 20250131 Free format text: ST27 STATUS EVENT CODE: A-1-1-U10-U11-U102 (AS PROVIDED BY THE NATIONAL OFFICE); EVENT TEXT: MAINTENANCE FEE PAYMENT PAID IN FULL Effective date: 20250131 |
|
| W00 | Other event occurred |
Free format text: ST27 STATUS EVENT CODE: A-1-1-W10-W00-W100 (AS PROVIDED BY THE NATIONAL OFFICE); EVENT TEXT: LETTER SENT Effective date: 20250422 |
|
| D11 | Substantive examination requested |
Free format text: ST27 STATUS EVENT CODE: A-1-2-D10-D11-D155 (AS PROVIDED BY THE NATIONAL OFFICE); EVENT TEXT: ALL REQUIREMENTS FOR EXAMINATION DETERMINED COMPLIANT Effective date: 20250428 |
|
| D00 | Search and/or examination requested or commenced |
Free format text: ST27 STATUS EVENT CODE: A-2-2-D10-D00-D120 (AS PROVIDED BY THE NATIONAL OFFICE); EVENT TEXT: VOLUNTARY SUBMISSION OF PRIOR ART RECEIVED Effective date: 20250617 |
|
| W00 | Other event occurred |
Free format text: ST27 STATUS EVENT CODE: A-2-2-W10-W00-W111 (AS PROVIDED BY THE NATIONAL OFFICE); EVENT TEXT: CORRESPONDENT DETERMINED COMPLIANT Effective date: 20250618 |
|
| W00 | Other event occurred |
Free format text: ST27 STATUS EVENT CODE: A-2-2-W10-W00-W100 (AS PROVIDED BY THE NATIONAL OFFICE); EVENT TEXT: LETTER SENT Effective date: 20250825 |
|
| MFA | Maintenance fee for application paid |
Free format text: FEE DESCRIPTION TEXT: MF (APPLICATION, 5TH ANNIV.) - STANDARD Year of fee payment: 5 |
|
| U00 | Fee paid |
Free format text: ST27 STATUS EVENT CODE: A-2-2-U10-U00-U101 (AS PROVIDED BY THE NATIONAL OFFICE); EVENT TEXT: MAINTENANCE REQUEST RECEIVED Effective date: 20250912 |
|
| U11 | Full renewal or maintenance fee paid |
Free format text: ST27 STATUS EVENT CODE: A-2-2-U10-U11-U102 (AS PROVIDED BY THE NATIONAL OFFICE); EVENT TEXT: MAINTENANCE FEE PAYMENT PAID IN FULL Effective date: 20250912 |
|
| D00 | Search and/or examination requested or commenced |
Free format text: ST27 STATUS EVENT CODE: A-2-2-D10-D00-D123 (AS PROVIDED BY THE NATIONAL OFFICE); EVENT TEXT: PRIOR ART DISCLOSURE DETERMINED COMPLIANT Effective date: 20251001 |
|
| W00 | Other event occurred |
Free format text: ST27 STATUS EVENT CODE: A-2-2-W10-W00-W100 (AS PROVIDED BY THE NATIONAL OFFICE); EVENT TEXT: LETTER SENT Effective date: 20251001 |
|
| D15 | Examination report completed |
Free format text: ST27 STATUS EVENT CODE: A-2-2-D10-D15-D126 (AS PROVIDED BY THE NATIONAL OFFICE); EVENT TEXT: EXAMINER'S REPORT Effective date: 20251023 |
|
| W00 | Other event occurred |
Free format text: ST27 STATUS EVENT CODE: A-2-2-W10-W00-W100 (AS PROVIDED BY THE NATIONAL OFFICE); EVENT TEXT: LETTER SENT Effective date: 20260714 |